MNTA: Yes. facts.
1. MNTA has the only generic approval despite TEVA's longer lead time.
2. TEVA doesn't know if and/or when they will get approval; thus, how could any "analyst" contact that you have possess relevant info?
3. There appear to be substantial unanswered questions surrounding the TEVA Lovenox program, otherwise, you wouldn't be asking around nor posting.
4. TEVA doesn't have sufficient reason to disclose negative developments, as opposed to MNTA.
The only useful speculation seems to be restricted to why MNTA hasn't yet appreciated. The lack of a clear answer does not reflect upon TEVA, necessarily. Recall the "Efficient Market Hypothesis?"
Lets agree to re-visit this in 2-months to see if you're correct re MNTA's market cap.
Market Data 
Markets 
AI
